Author

Melissa Marton

New York Genome Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genomics· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:variant calling· 2 Assay:whole-genome sequencing· 2 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Adam J. WidmaniD· 2 shared Alexandre Pellan ChengiD· 2 shared Anushri AroraiD· 2 shared Ashish SaxenaiD· 2 shared Dan Avi LandauiD· 2 shared Daniel HalmosiD· 2 shared Dennie Tompers FrederickiD· 2 shared Dina ManaaiD· 2 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

Adam J. WidmanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GenomicsNature MedicinePeer-reviewedJun 1, 2024

Machine learning guided signal enrichment for ultrasensitive plasma tumor burden monitoring

Adam J. Widman, Minita J. Shah, Amanda Frydendahl…·Dan Avi Landau

This paper introduces MRD-EDGE, a machine learning platform for ultrasensitive ctDNA detection in plasma WGS, showing improved sensitivity and broader applicability for MRD monitoring.

138 citationstop 1%

humanwhole-genome sequencing

𝕏 PostBluesky

GenomicsbioRxivPreprintNov 17, 2022

Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring

Alexandre Pellan Cheng, Adam J. Widman, Anushri Arora…·Dan Avi Landau

This study applies low-cost whole genome sequencing to detect circulating tumor DNA at high sensitivity in plasma samples, achieving error rates as low as 10^-7 and enabling cancer monitoring without matched tumor sequencing.

8 citations

mousehuman

𝕏 PostBluesky